Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT00268970
- Lead Sponsor
- Agennix
- Brief Summary
The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
- Detailed Description
This trial is designed to study the efficacy and safety of a novel oral platinum analog, satraplatin, in combination with another chemotherapy drug, paclitaxel, for the first line of treatment (patients who have not received chemotherapy for disease that has metastasized) of patients with advanced NSCLC.
WHAT IS SATRAPLATIN:
Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Histologically confirmed advanced NSCLC
- Patients must not have received any prior antineoplastic chemotherapy or investigational product for lung cancer prior to study entry.
- Patients must have at least one unidimensionally measurable lesion definable by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- ECOG performance status of ≤ 2.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To examine overall response rates in patients with advanced NSCLC treated with a first-line regimen of satraplatin and paclitaxel 3 months
- Secondary Outcome Measures
Name Time Method To examine time to tumor progression, overall survival, and safety in patients with advanced NSCLC treated with a first-line regimen of satraplatin and paclitaxel 3 months
Trial Locations
- Locations (1)
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States